Regulatory & PolicyFor more than thirty years, U.S. healthcare has wrestled with the contentious process of prior authorization. Despite fervent hopes that artificial intelligence will resolve its inefficiencies and inequities, the core battle remains deeply rooted in structural issues. This analysis examines why AI, despite its promise, cannot end the entrenched struggles surrounding prior authorization and what its implementation may actually bring to the table.
Michael Torres·Jul 12, 2026
Regulatory & PolicyThe intersection of menopause and chronic disease presents unique challenges for high-risk patients and the healthcare system at large. Despite its prevalence, menopause remains under-recognized as a cost driver, with multifaceted effects on disease management, quality of life, and healthcare spending. In-depth analysis reveals that its impact stretches beyond visible symptoms, seeping into care complexity, treatment plans, and long-term health economics.
Michael Torres·Jul 10, 2026 
Regulatory & PolicyIn an era when the idea of Ebola becoming an enduring presence in parts of Africa was once unthinkable, the current situation in countries such as the Democratic Republic of Congo and Uganda is forcing a critical reassessment. Could Ebola evade control and become a standing, unsolvable public health threat? This piece explores that sobering scenario, the stakes for local and global health authorities, and the lessons that must guide future response.
Michael Torres·Jul 7, 2026 
Biotech InnovationThe biopharmaceutical landscape continues to see vigorous acquisition activity in the rare disease space, with Ipsen initiating its second major buyout in a single week. This article explores the strategic importance and broader industry context of Ipsen’s $796 million agreement to acquire Memo Therapeutics and its promising monoclonal antibody program. The move reflects persistent enthusiasm for rare disease innovation and the ongoing drive for portfolio expansion through M&A.
Michael Torres·Jul 2, 2026 
Biopharmaceutical IndustryAs BioCryst Therapeutics ends its in-house discovery programs, the company joins a cohort of firms adapting to shifting industry realities through layoffs and restructuring. This marks a significant strategic pivot aimed at refocusing resources and responding to market and financial pressures.
Michael Torres·Jul 1, 2026 
Regulatory & PolicyViridian’s newly approved therapy Lumvoa offers an alternative to Amgen’s market-dominating Tepezza for thyroid eye disease, potentially reshaping patient access and competitive dynamics in this specialty area. The FDA’s decision could have broader implications for pricing, market share, and innovation in rare autoimmune disorders.
Michael Torres·Jun 29, 2026 
Healthcare InvestmentBefore allocating ever-larger sums to healthcare, policymakers, payers, and the public must grapple with measuring value—not just output. This debate centers on determining how much system capacity is needed, which outcomes justify investment, and how to align funding with real, measurable improvements in health.
Michael Torres·Jun 28, 2026 
Regulatory & PolicyThe European Commission’s investigation into Sanofi’s alleged antitrust violations marks a significant development in maintaining fair competition across the continent’s pharmaceutical sector. At stake are key principles of fair market behavior and accurate scientific communication, set against the backdrop of public health priorities and evolving regulatory oversight.
Michael Torres·Jun 27, 2026 
Biotech InnovationThe acquisition of Bio-Techne by Merck KGaA for $11 billion represents one of 2026’s most significant biopharma moves, positioning Merck squarely at the forefront of cell therapy innovation. This deal highlights a shifting landscape as companies seek to secure advanced manufacturing technologies and fortify their pipeline.
Michael Torres·Jun 26, 2026 
Biopharmaceutical IndustryThe US policy landscape for drug pricing is reshaping rapidly, with biopharma dealmakers scrambling to protect commercial and strategic interests. Trump’s Most Favored Nation (MFN) pricing policy introduces new challenges, and the result is a fundamental change in tactics and contract structuring across both biotech and pharmaceutical business development teams.
Michael Torres·Jun 23, 2026 
Regulatory & PolicyThe FDA’s reversal on Regenxbio’s gene therapy application is emblematic of the regulator’s evolving approach toward cutting-edge, high-risk therapies for rare diseases. The move reflects both ongoing scientific debates and the urgent needs of patients with few (or no) alternatives. Today’s reconsideration provides new hope for transformative genetic treatments targeting devastating pediatric disorders.
Michael Torres·Jun 22, 2026 
Biopharmaceutical IndustryThe biopharma landscape is witnessing accelerated consolidation as major players, including AbbVie, advance a run of strategic acquisitions. By acquiring Apogee Therapeutics for nearly $11 billion, AbbVie underscores its intent to remain competitive in the burgeoning immunology market. This move highlights the intensifying competition and the critical importance of pipeline innovation in the post-Humira era for AbbVie and its major rivals.
Michael Torres·Jun 22, 2026 